Clinical trial · Interventional
Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
NCT07513116CI-TRIAL-00108087not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Evaluating | — | UNRESOLVED | — |
| Intermittent Fasting | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intermittent fasting | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intermittent fasting
- description
- Fast for 16 consecutive hours each day and have an 8-hour window for eating.
- interventionNames
- Other: intermittent fasting
Primary outcomes (1)
- measure
- Safety and adverse events (AEs).
- timeFrame
- Through study completion; an average of 1 year.
- description
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits. * Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification. * High-risk status may include one or more of the following: * Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk * Family history of pancreatic ductal adenocarcinoma (PDAC) * Presence of pancreatic cysts or precursor lesions (e.g., IPMN, MCN) * New-onset diabetes mellitus is considered suspicious for pancreatic cancer * History of recurrent or chronic pancreatitis * Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals. * Participants are able to understand and are willing to sign a written informed consent document. * Both English-speaking and non-English-speaking participants are eligible for participation * Participants are willing to make a change in eating time patterns. * Participants are willing to provide App-tracked fasting time data over the course of the study. Exclusion Criteria * BMI \< 18.5 Kg/m2 * Documented history of symptomatic hypoglycemia * Pregnant or breastfeeding women * Cognitively impaired individuals
References
Publications (0)
Data not yet available
No reference posted for this study.